Arpeggio Bio
Arpeggio Bio develops drugs targeting transcription factors using AI…
Arpeggio Bio is a pioneering pharmaceutical company that develops drugs targeting transcription factors using AI and high-throughput RNA-sequencing. With $20M in venture funding, we've targeted "undruggable" proteins like NRF2, TEAD, and GPX4 where our lead program is rapidly progressing towards a DC for the treatment of IO-resistant melanoma. With partnerships with J&J and FORMA, we've validated our platform in rare disease and inflammation with a significant Phase I success.
- Category
- Analytics
- Pricing
- freemium
- Difficulty
- beginner
Y Combinator batch: Summer 2019
Directory records are starting points for research. Check the official website for current features, pricing and availability. A catalog sync is not a hands-on product review.
Features
- AI-Powered
- API Access
Industries
- Healthcare